Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies

Hdl Handle:
http://hdl.handle.net/10144/601276
Title:
Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies
Authors:
Burri, C; Yeramian, PD; Allen, JL; Merolle, A; Serge, KK; Mpanya, A; Lutumba, P; Mesu, VK; Bilenge, CM; Lubaki, JP; Mpoto, AM; Thompson, M; Munungu, BF; Manuel, F; Josenando, T; Bernhard, SC; Olson, CA; Blum, J; Tidwell, RR; Pohlig, G
Journal:
PLoS Neglected Tropical Diseases
Abstract:
Sleeping sickness (human African trypanosomiasis [HAT]) is caused by protozoan parasites and characterized by a chronic progressive course, which may last up to several years before death. We conducted two Phase 2 studies to determine the efficacy and safety of oral pafuramidine in African patients with first stage HAT.
Publisher:
Public Library of Science
Issue Date:
16-Feb-2016
URI:
http://hdl.handle.net/10144/601276
DOI:
10.1371/journal.pntd.0004362
PubMed ID:
26881924
Type:
Article
Language:
en
ISSN:
1935-2735
Appears in Collections:
Trypanosomiasis/Sleeping Sickness

Full metadata record

DC FieldValue Language
dc.contributor.authorBurri, Cen
dc.contributor.authorYeramian, PDen
dc.contributor.authorAllen, JLen
dc.contributor.authorMerolle, Aen
dc.contributor.authorSerge, KKen
dc.contributor.authorMpanya, Aen
dc.contributor.authorLutumba, Pen
dc.contributor.authorMesu, VKen
dc.contributor.authorBilenge, CMen
dc.contributor.authorLubaki, JPen
dc.contributor.authorMpoto, AMen
dc.contributor.authorThompson, Men
dc.contributor.authorMunungu, BFen
dc.contributor.authorManuel, Fen
dc.contributor.authorJosenando, Ten
dc.contributor.authorBernhard, SCen
dc.contributor.authorOlson, CAen
dc.contributor.authorBlum, Jen
dc.contributor.authorTidwell, RRen
dc.contributor.authorPohlig, Gen
dc.date.accessioned2016-03-12T10:36:40Zen
dc.date.available2016-03-12T10:36:40Zen
dc.date.issued2016-02-16en
dc.identifier.citationEfficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies. 2016, 10 (2):e0004362 PLoS Negl Trop Disen
dc.identifier.issn1935-2735en
dc.identifier.pmid26881924en
dc.identifier.doi10.1371/journal.pntd.0004362en
dc.identifier.urihttp://hdl.handle.net/10144/601276en
dc.description.abstractSleeping sickness (human African trypanosomiasis [HAT]) is caused by protozoan parasites and characterized by a chronic progressive course, which may last up to several years before death. We conducted two Phase 2 studies to determine the efficacy and safety of oral pafuramidine in African patients with first stage HAT.en
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen
dc.titleEfficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studiesen
dc.typeArticleen
dc.identifier.journalPLoS Neglected Tropical Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.